Cargando…

Non-response to rituximab therapy in rheumatoid arthritis is associated with incomplete disruption of the B cell receptor repertoire

OBJECTIVE: To gain more insight into the dynamics of lymphocyte depletion and develop new predictors of clinical response to rituximab in rheumatoid arthritis (RA). METHODS: RNA-based next-generation sequencing was used to analyse the B cell receptor (BCR) repertoire in peripheral blood and synovial...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pollastro, Sabrina, Klarenbeek, Paul L, Doorenspleet, Marieke E, van Schaik, Barbera D C, Esveldt, Rebecca E E, Thurlings, Rogier M, Boumans, Maria J H, Gerlag, Danielle M, Tak, Paul P, Vos, Koen, Baas, Frank, van Kampen, Antoine H C, de Vries, Niek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Rheumatoid Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788876/ https://www.ncbi.nlm.nih.gov/pubmed/31217169 http://dx.doi.org/10.1136/annrheumdis-2018-214898

Ejemplares similares

Computational Model Reveals Limited Correlation between Germinal Center B-Cell Subclone Abundancy and Affinity: Implications for Repertoire Sequencing
por: Reshetova, Polina, et al.
Publicado: (2017)

Extension Study of PF‐05280586, a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid Arthritis
por: Cohen, Stanley B., et al.
Publicado: (2018)

Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry
por: Salmon, J H, et al.
Publicado: (2015)

Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis
por: Tweehuysen, Lieke, et al.
Publicado: (2018)

Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study
por: Gerlag, Danielle M, et al.
Publicado: (2019)

Metabolomic profiling predicts outcome of rituximab therapy in rheumatoid arthritis
por: Sweeney, Shannon R, et al.
Publicado: (2016)

Efficacy and safety of rituximab in peripheral ulcerative keratitis associated with rheumatoid arthritis
por: Bonnet, Isabelle, et al.
Publicado: (2021)

Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study
por: Winthrop, Kevin L., et al.
Publicado: (2019)

Brief Report: Altered Innate Lymphoid Cell Subsets in Human Lymph Node Biopsy Specimens Obtained During the At‐Risk and Earliest Phases of Rheumatoid Arthritis
por: Rodríguez‐Carrio, Javier, et al.
Publicado: (2016)

Safety and Efficacy of Atacicept in Combination With Rituximab for Reducing the Signs and Symptoms of Rheumatoid Arthritis: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Pilot Trial
por: van Vollenhoven, R. F., et al.
Publicado: (2015)

Internalization of Rituximab and the Efficiency of B Cell Depletion in Rheumatoid Arthritis and Systemic Lupus Erythematosus
por: Reddy, Venkat, et al.
Publicado: (2015)

Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic
por: Druce, Katie L, et al.
Publicado: (2017)

Features of the Synovium of Individuals at Risk of Developing Rheumatoid Arthritis: Implications for Understanding Preclinical Rheumatoid Arthritis
por: de Hair, MJH, et al.
Publicado: (2014)

Genomic repertoires linked with pathogenic potency of arthritogenic Prevotella copri isolated from the gut of patients with rheumatoid arthritis
por: Nii, Takuro, et al.
Publicado: (2023)

Effect of Fcγ-receptor 3a (FCGR3A) gene polymorphisms on rituximab therapy in Hungarian patients with rheumatoid arthritis
por: Pál, Ildikó, et al.
Publicado: (2017)

Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis
por: Juge, Pierre-Antoine, et al.
Publicado: (2017)

Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39
por: Spiliopoulou, Athina, et al.
Publicado: (2019)

How to enhance recruitment of individuals at risk of rheumatoid arthritis into trials aimed at prevention: understanding the barriers and facilitators
por: van Boheemen, Laurette, et al.
Publicado: (2021)

A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Rituximab or a second anti–tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti–tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register
por: Soliman, Moetaza M, et al.
Publicado: (2012)

Somatic Variation of T-Cell Receptor Genes Strongly Associate with HLA Class Restriction
por: Klarenbeek, Paul L., et al.
Publicado: (2015)

Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trial
por: ter Wee, Marieke M, et al.
Publicado: (2017)

Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre‐Specified Analysis of Two Phase III Trials
por: Combe, Bernard, et al.
Publicado: (2016)

Smartphone‐Assisted Patient‐Initiated Care Versus Usual Care in Patients With Rheumatoid Arthritis and Low Disease Activity: A Randomized Controlled Trial
por: Seppen, Bart, et al.
Publicado: (2022)

Microbiota‐Dependent Involvement of Th17 Cells in Murine Models of Inflammatory Arthritis
por: Evans‐Marin, Heather, et al.
Publicado: (2018)

DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability
por: Verstappen, M, et al.
Publicado: (2020)

Gaming for Adherence to Medication using Ehealth in Rheumatoid arthritis (GAMER) study: a randomised controlled trial
por: Pouls, Bart P H, et al.
Publicado: (2022)

Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial
por: van Mulligen, Elise, et al.
Publicado: (2020)

Value of imaging detected joint inflammation in explaining fatigue in RA at diagnosis and during the disease course: a large MRI study
por: Matthijssen, X M E, et al.
Publicado: (2021)

Initial validation and results of the Symptoms in Persons At Risk of Rheumatoid Arthritis (SPARRA) questionnaire: a EULAR project
por: van Beers-Tas, Marian H, et al.
Publicado: (2018)

Intermetatarsal Bursitis, a Novel Feature of Juxtaarticular Inflammation in Early Rheumatoid Arthritis Related to Clinical Signs: Results of a Longitudinal Magnetic Resonance Imaging Study
por: van Dijk, Bastiaan T., et al.
Publicado: (2022)

Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data
por: Alemao, Evo, et al.
Publicado: (2016)

What do patients prefer? A multinational, longitudinal, qualitative study on patient-preferred treatment outcomes in early rheumatoid arthritis
por: Van der Elst, Kristien, et al.
Publicado: (2020)

Hand function is already reduced before RA development and reflects subclinical tenosynovitis
por: Krijbolder, Doortje Isabelle, et al.
Publicado: (2023)

Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
por: van der Heijde, Desirée, et al.
Publicado: (2018)

Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time
por: Boone, Niels W., et al.
Publicado: (2019)

Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice
por: Boone, Niels W, et al.
Publicado: (2019)

Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone
por: Keystone, Edward C, et al.
Publicado: (2017)

The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries
por: Finckh, A, et al.
Publicado: (2015)

Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study
por: Jansen, Diahann T S L, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4uv4rbpv3a4k43tmepct7qs7ai